In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in management of patients with primary biliary cholangitis. This progressive, autoimmune disease was previously referred to as primary biliary cirrhosis. One notable change discussed is approval of obeticholic acid for use in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid.
This activity was developed for gastroenterologists, hepatologists, immunologists, primary care physicians, and other health care professionals who have an interest in primary biliary cholangitis.
|Available Credit:||1.00 AMA PRA Category 1 Credit™.|
|Opens:||May 24, 2017|
|Expires:||May 23, 2018|
Primary Care Physicians
Other Health Care Providers